staphylokinase

Biologicalexperimental

Clinical trial activity

8 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
4
Phase 3
5
Phase 4
3

Earliest trial started Oct 1, 2010 (NCT01305226)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 3 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • thr-100

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06362746Phase 3May 23, 2024Government of Russia, Supergene, LLC
NCT05410925Phase 4Jan 1, 2023Nanjing Medical University
NCT05372718Phase 3Dec 1, 2022Government of Russia, Supergene, LLC
NCT05135546Phase 2/Phase 3 (Phase 3)Dec 1, 2021Russian Academy of Medical Sciences, Supergene, LLC
NCT05649696Phase 4Oct 29, 2021Nanjing Medical University
NCT05023681Phase 4Sep 1, 2021Nanjing Medical University
NCT04688320Phase 3Dec 15, 2020Pirogov Russian National Research Medical University, Supergene, LLC
NCT01305226Phase 3Oct 1, 2010Bharat Biotech International Limited
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Supergene, LLCFor profit4412020
Nanjing Medical UniversityAcademic/Hospital3312021
Government of RussiaGovernment2012022
Bharat Biotech International LimitedFor profit1112010
Pirogov Russian National Research Medical UniversityAcademic/Hospital1012020
Russian Academy of Medical SciencesAcademic/Hospital1012021
6 organizations
Page 1 / 1